SCHEMBL22283972

SCHEMBL22283972

CNC(C(=O)NC(C(=O)N(C)C(/C=C(\C)C(=O)O)C(C)C)C(C)(C)C)C(C)(C)c1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.76

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 2/20 0.76
▸ STAT6 P42226 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22307898 1.00 TUBB1 (0.76) TUBB1STAT6
SCHEMBL20732483 1.00 TUBB1 (0.76) TUBB1STAT6
SCHEMBL20732168 1.00 TUBB1 (0.76) TUBB1STAT6
SCHEMBL22069865 0.91 TUBB1 (0.69) TUBB1STAT6
SCHEMBL22069864 0.91 TUBB1 (0.69) TUBB1STAT6
SCHEMBL27095055 0.91 TUBB1 (0.69) TUBB1STAT6
SCHEMBL22309195 0.90 TUBB1 (0.80) TUBB1STAT6
SCHEMBL22069847 0.90 TUBB1 (0.80) TUBB1STAT6
SCHEMBL6669488 0.90 TUBB1 (0.80) TUBB1STAT6
SCHEMBL6669491 0.90 TUBB1 (0.80) TUBB1STAT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059732-A1 Antibody-Drug Conjugates Including Hemiasterlin Derivative Sumitomo Pharma Co., Ltd. (JP) 2024-02-22 — — US disclosed
US-11795195-B2 Antibody-drug conjugates including hemiasterlin derivative Sumitomo Pharma Co., Ltd. (JP) 2023-10-24 — — US disclosed
US-20200247847-A1 Antibody-Drug Conjugates Including Hemiasterlin Derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795195-B2 Antibody-drug conjugates including hemiasterlin derivative HSD3B2, HSD3B1, HSD11B2 TUBB1 624/4885STAT6 3556/4885
US-20240059732-A1 Antibody-Drug Conjugates Including Hemiasterlin Derivative HSD3B2, HSD3B1, HSD11B2 TUBB1 624/4885STAT6 3556/4885
US-20200247847-A1 Antibody-Drug Conjugates Including Hemiasterlin Derivative HSD3B2, HSD3B1, HSD11B2 TUBB1 624/4885STAT6 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback